




PHARMACEUTICAL 2022

Phathom Pharmaceuticals Inc.
Rank 375 of 466





RealRate

PHARMACEUTICAL 2022

Phathom Pharmaceuticals Inc. Rank 375 of 466



The relative strengths and weaknesses of Phathom Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Phathom Pharmaceuticals Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 24% points. The greatest weakness of Phathom Pharmaceuticals Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 121% points.

The company's Economic Capital Ratio, given in the ranking table, is -13%, being 91% points below the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	186,526
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	18,921
Liabilities, Non-Current	98,354
Other Assets	2,255
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	-8,803
Other Revenues	0
Property and Equipment	650
Research and Development	72,338
Selling, General and Administrative Expense	62,742

Output Variable	Value in 1000 USD
Assets	189,431
Liabilities	117,275
Expenses	135,080
Revenues	0
Stockholders Equity	72,156
Net Income	-143,883
Comprehensive Net Income	-143,883
Economic Capital Ratio	-13%